Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
Nyxoah SA is offering 1,215,964 ordinary shares at $4.6304 (€4.00) per share, raising gross proceeds of about $5.6 million and estimated net proceeds of $5.5 million (€4.8 million). The shares are sold directly to investors without an underwriter, and trade on Nasdaq and Euronext Brussels under “NYXH.” Nyxoah plans to use the cash to support the U.S. launch and international commercialization of its Genio system for obstructive sleep apnea, fund clinical data generation and physician-led studies, advance R&D, build a pipeline in OSA monitoring and diagnostics, and for general corporate purposes.
Alongside this deal, the company has arranged a €17.0 million private placement of 4,265,714 ordinary shares at €4.00 and a separate offering of up to €45.0 million in amortizing senior unsecured convertible notes, expected to yield about €41.4 million in gross proceeds. As of September 30, 2025, Nyxoah had 37,544,782 ordinary shares outstanding, which would increase to 38,760,746 after this offering, before giving effect to the private placement, notes conversion, or warrant exercises.
Nyxoah SA announced a multi-part financing to support commercialization of its Genio system and ongoing R&D. The company agreed to a private placement of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million, expected to close on or about November 18, 2025, subject to customary conditions.
Separately, Nyxoah entered a registered direct offering of ordinary shares at U.S.$4.6304 per share for aggregate gross proceeds of approximately U.S.$5.6 million, also expected to close on or about November 18, 2025. In addition, the company signed a convertible notes deal for up to €45.0 million aggregate principal amount at an 8.0% original issue discount, issued in two €22.5 million tranches; assuming both tranches, gross proceeds total approximately €41.4 million. The notes bear 6.5% interest, mature three years from issuance, and amortize quarterly over 12 installments, with optional share-settled payments priced per the bond instrument. Initial conversion pricing is set at 125% of the private placement price for the first tranche.
Proceeds across the transactions are designated for U.S. and ex-U.S. commercialization, clinical data, R&D and cost reductions, pipeline and collaborations, and general corporate purposes.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah SA submitted a Form 6-K as a foreign private issuer to furnish a company press release. The filing states that on September 23, 2025, Nyxoah issued a press release, which is attached as Exhibit 99.1. The exhibit is being furnished rather than filed, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Nyxoah SA has entered into an underwriting agreement with Morgan Stanley, Stifel and Cantor Fitzgerald to conduct an underwritten public offering of ordinary shares under its existing shelf registration on Form F-3. The company has granted the underwriters a 30-day option to buy additional shares and expects the offering to close around September 23, 2025, subject to customary conditions.
Nyxoah anticipates receiving net proceeds from this equity raise, after underwriting fees and expenses, and states that, based on current plans, the cash from this offering together with existing cash, cash equivalents and financial assets should be sufficient to fund operating expenses and capital expenditures for an extended period, as outlined in the cash runway discussion. The filing also notes standard indemnification provisions and includes the underwriting agreement, legal opinion and related press releases as exhibits.
Nyxoah SA reported that it has filed a patent infringement lawsuit in the United States against Inspire Medical Systems, Inc.. The suit, filed in the District of Delaware, alleges that Inspire’s Inspire IV and Inspire V devices infringe three Nyxoah U.S. patents and seeks injunctive relief and damages. Information about the lawsuit is furnished via a press release attached as Exhibit 99.1 and the lawsuit description is incorporated by reference into Nyxoah’s existing Form S-8 and Form F-3 registration statements.